25+ years of experience
Susan joined Citeline in 2004, building out clinical trials content and processes in oncology and launching Citeline’s custom analytics and consulting services before transitioning to her current role.
Prior to that, she worked in corporate market analytics at Ipsen and owned her own consulting business, specializing in competitive and market intelligence with companies including Decision Resources and Fuld & Company.
Driving product enhancements to address industry trends and client needs (in biomarkers, companion diagnostics, and real world evidence, to name a few), are among Susan’s most important contributions during her tenure at Citeline.
Susan writes For
By Susan Danheiser 09 Jul 2018
The timing of when sponsors report clinical trials in the public domain continues to be a topic of interest. Despite efforts to regulate and encourage prospective reporting of study starts, delayed reporting remains and is a factor that is often overlooked when evaluating clinical trial trends. Here, we examine the magnitude of clinical trial reporting delays and how they can be accounted for in your analyses.
Topic Clinical trials